Dcf Advisers, LLC Vir Biotechnology, Inc. Transaction History

Dcf Advisers, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$9.14 - $24.62 $411,300 - $1.11 Million	-45,000 Reduced 81.82%	10,000 $93,000
Q2 2023 Aug 09, 2023	SELL	$23.2 - $27.29 $162,400 - $191,030	-7,000 Reduced 11.29%	55,000 $1.35 Million
Q1 2023 May 15, 2023	BUY	$22.26 - $30.85 $845,880 - $1.17 Million	38,000 Added 158.33%	62,000 $1.44 Million
Q4 2022 Feb 13, 2023	BUY	$19.96 - $28.22 $479,040 - $677,280	24,000 New	24,000 $607,000
Q1 2022 May 13, 2022	SELL	$21.19 - $40.01 $423,800 - $800,200	-20,000 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$30.97 - $54.03 $247,760 - $432,240	-8,000 Reduced 28.57%	20,000 $837,000
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $555,922 - $868,767	15,929 Added 131.96%	28,000 $1.22 Million
Q2 2021 Aug 13, 2021	BUY	$38.75 - $51.0 $189,061 - $248,829	4,879 Added 67.84%	12,071 $571,000
Q1 2021 May 12, 2021	SELL	$26.34 - $83.07 $363,702 - $1.15 Million	-13,808 Reduced 65.75%	7,192 $369,000
Q4 2020 Feb 12, 2021	SELL	$25.51 - $43.38 $127,550 - $216,900	-5,000 Reduced 19.23%	21,000 $562,000
Q3 2020 Nov 13, 2020	BUY	$28.28 - $53.6 $523,180 - $991,600	18,500 Added 246.67%	26,000 $893,000
Q2 2020 Aug 13, 2020	BUY	$27.89 - $47.86 $209,175 - $358,950	7,500 New	7,500 $307,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.